XML 22 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Agreements (Details 2) (USD $)
3 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 40 Months Ended 1 Months Ended
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2014
Amgen
Jun. 30, 2013
Amgen
Jun. 30, 2012
Amgen
Jun. 30, 2014
Amgen
Future Technological Improvements
Jun. 30, 2014
Amgen
Exclusive license
Development milestones
Phase II clinical trial
Jun. 30, 2014
Amgen
Development and Commercialization License
Oct. 31, 2013
Amgen
Development and Commercialization License
Maximum
Oct. 31, 2013
Amgen
Development and Commercialization License
Development milestones
Jun. 30, 2014
Amgen
Development and Commercialization License
Development milestones
IND application effective
Oct. 31, 2013
Amgen
Development and Commercialization License
Regulatory milestones
Oct. 31, 2013
Amgen
Development and Commercialization License
Sales milestones
Oct. 31, 2013
Amgen
Development and Commercialization License
Exclusive license
Dec. 31, 2012
Amgen
Development and Commercialization License
Exclusive license
Nov. 30, 2009
Amgen
Development and Commercialization License
Exclusive license
Sep. 30, 2009
Amgen
Development and Commercialization License
Exclusive license
Jun. 30, 2014
Amgen
Development and Commercialization License
Exclusive license
item
Dec. 31, 2012
Amgen
Development and Commercialization License
Exclusive license
item
Nov. 30, 2011
Amgen
Development and Commercialization License
Exclusive license
Undisclosed Target
IND application effective
item
May 31, 2013
Amgen
Development and Commercialization License
Non-exclusive license
item
Collaborative Agreements disclosures                                                            
Potential milestone payments receivable                               $ 3,000,000   $ 34,000,000 $ 9,000,000 $ 1,000,000 $ 20,000,000 $ 5,000,000                
Number of single-target licenses                                                     4 3   1
Fee received per license                                               1,000,000 1,000,000 1,000,000     1,000,000 500,000
Fee received on conversion of non-exclusive license agreement to an exclusive license                                             500,000              
Estimated utilization period after commercialization                                 10 years                          
Discount rate (as a percent)                                 13.00%                          
Remaining arrangement consideration to be recognized as license revenue                             430,000   2,200,000                          
Estimated term of development and commercialization license                             25 years                              
Number of compounds under development and commercialization licenses                                                         2  
Number of milestone payments                                                         2  
Costs related to the research and development services 25,787,000 38,280,000 20,862,000 22,029,000 20,399,000 21,318,000 21,656,000 23,700,000 106,958,000 87,073,000 69,192,000 179,000 174,000 423,000                                
Costs related to clinical materials sold                       $ 664,000 $ 670,000 $ 649,000